Update! Top line data expected late 2024
$Sage Therapeutics(SAGE.US$ Sage Therapeutics Says Phase 2 SURVEYOR Study Strengthens Cognitive Impact Of Huntington's Disease! For Participants With Hd Got Dalzanemdor or Placebo, Dalzanemdor Was Generally Well-Tolerated With No New Safety Signals Observed
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Trytosaveabit OP : Huntington Disease Drug Meets Main Goal in Mid-Stage Study